Of the 19 selected mandatory QIs, we reached threshold requirements in 9 QIs in all three age groups, in 3 of them with 100% completeness (in cancers with a pre-operative diagnosis, in cancers discussed by a multidisciplinary team, and in HER2 invasive cancers treated with neo-adjuvant chemotherapy plus trastuzumab). The gene discussed is ERBB2; the disease is cancer.